<?xml version="1.0" encoding="UTF-8"?>
<p>ARDS is seen fairly often in the context of these diseases, and has been reported in up to 30% of SARS patients (Huang 
 <italic>et al</italic>. 
 <xref rid="bib23" ref-type="bibr">2005</xref>), 40% of MERS patients (Saad 
 <italic>et al</italic>. 
 <xref rid="bib52" ref-type="bibr">2014</xref>) and approximately 30% of hospitalized COVID-19 patients (Huang 
 <italic>et al</italic>. 
 <xref rid="bib22" ref-type="bibr">2020</xref>). Interestingly, a full 93% (50/54, 
 <italic>P </italic>&lt; 0.0001) of patients who developed ARDS in a Chinese cohort were non-survivors (Zhou 
 <italic>et al</italic>. 
 <xref rid="bib75" ref-type="bibr">2020</xref>).
</p>
